Article Text

Download PDFPDF
Case report
Intravitreal bevacizumab in treatment of iris metastasis from primary lung carcinoma
  1. Vishal Raval1,
  2. Merlin Saldanha2,
  3. Ruchi Mittal3 and
  4. Taraprasad Das4
  1. 1 Vitreoretina, LVPEI, Vijayawada, Andra Pradesh, India
  2. 2 LV Prasad Eye Institute, Visakhapatnam, Andhra Pradesh, India
  3. 3 Ophthalmic Pathology, LV Prasad Eye Institute, Bhubaneswar, Odisha, India
  4. 4 LV Prasad Eye Institute, Hyderabad, Telangana, India
  1. Correspondence to Dr Vishal Raval, drvishalraval{at}gmail.com

Abstract

Iris metastases secondary to primary malignancy are rare and usually have poor overall survival. We report a case of a man aged 60 years who presented with chief complaints of progressive pain and redness of right eye of 5 days duration. Slit-lamp examination revealed a greyish white irregular nodular mass, arising from anterior iris surface reaching up to mid-periphery. With a clinical suspicion of iris metastasis, systemic investigations were requested. CT scan of chest reported a well-defined lobulated lesion in the lower lobe of lung with presence of multiple satellite nodules in both lungs suggestive of primary malignant neoplasm of lung. Tissue diagnosis was obtained through an iris lesion biopsy, which was opted for relative ease of approach. Histopathology and immunohistochemistry confirmed the diagnosis of iris metastasis secondary to non-keratinising squamous cell carcinoma of lung. Local intravitreal injection of antivascular endothelial growth factor was administered for tumour regression along with systemic chemotherapy.

  • Lung Cancer (oncology)
  • Iris
  • Pathology
  • Eye

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Concept and design: VR. Data collection: MS. Analysis and Interpretation: VR. Writing of manuscript: MS, VR. Critical review of manuscript: RM, TD.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.